Phathom Pharmaceuticals Inc

NASDAQ:PHAT   10:09:21 AM EDT
36.60
-1.65 (-4.31%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Phathom Pharmaceuticals, Inc. Stock, NASDAQ:PHAT

2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE, IL 60089
United States of America
Phone: 650-325-5156
Number of Employees:

Description

PHATHOM PHARMACEUTICALS, INC. is a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Our initial product candidate, vonoprazan, is an oral small molecule potassium competitive acid blocker, or P-CAB. P-CABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has shown rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits over standard of care treatments as a single agent in the treatment of gastroesophageal reflux disease, or GERD, and in combination with antibiotics for the treatment of Helicobacter pylori, or H. pylori, infection. Takeda Pharmaceutical Company Limited, or Takeda, developed vonoprazan and has received marketing approval in nine countries in Asia and Latin America. Vonoprazan generated over $500 million in net sales in its fourth full year on the market since its approval in Japan in late 2014. In May 2019, we in-licensed the U.S., European, and Canadian rights to vonoprazan from Takeda. We believe we can leverage Takeda??s extensive clinical data, including results from 17 Phase 3 clinical trials, to advance vonoprazan through pivotal trials in the United States and Europe. We plan to initiate two pivotal Phase 3 clinical trials in the fourth quarter of 2019 for vonoprazan: one for the treatment of erosive GERD, also known as erosive esophagitis, and a second for the treatment of H. pylori infection. We expect to report top-line data from both trials in 2021. We believe that the successful completion of our Phase 3 clinical trials, together with the existing clinical data, will support regulatory submissions in 2021 and 2022 for marketing approval for the treatment of H. pylori infection and erosive esophagitis, respectively. In August 2019, we received qualified infectious disease product, or QIDP, designation from the U.S. Food and Drug Administration, or FDA, for vonoprazan in combination with certain antibiotics for the treatment of H. pylori infection which provides, among other benefits, extension of any regulatory exclusivity and potential eligibility for priority review. Vonoprazan has the potential to be the first gastric anti-secretory agent from a novel class approved in the United States, Europe, or Canada in over 30 years.